Swiss-based biopharmaceutical group, Debiopharm Group, Friday announced the launching of prostate cancer drug Pamorelin LA in India by Indian pharma major Dr. Reddy's Laboratories (RDY).
Pursuant to the agreement, the Indian company has exclusive marketing and sales right for the drug that will be made available to urologists and oncologists in particular.
Commenting on the development Rolland-Yves Mauvernay, President and founder of Debiopharm Group said, "This major step enables us to implement our strategy in one of the most important markets in Asia."
The drug has been launched for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.